Pharma News

Olympus made its initial investment in Medi-Tate in November 2018, under an agreement that included the rights to distribute Medi-Tate products and gave Olympus an option to acquire 100% of the Israeli company at a later date. Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of benign prostatic hyperplasia (“BPH”). The company’s flagship product “iTind” has received a European CE mark and is FDA cleared for use in the U.S.

Innovators at Indian Institute of Science Education and Research (IISER), Bhopal have developed a unique ‘Crowd and Mask’ Monitoring System to prevent COVID-19 from spread. This one-of-its-kind low cost Artificial Intelligence (AI)-enabled device is portable and easy to deploy across various locations, says a statement released by the institution.

Scientists from Raman Research Institute (RRI) have developed a new technique to measure DNA modifications that can have applications in the early diagnosis of multiple diseases like Cancer, Alzheimer’s, and Parkinson’s diseases.

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of the TYRX™ Absorbable Antibacterial Envelope (TYRX Envelope) - an absorbable, single-use, antibacterial envelope designed to stabilize a cardiac implantable electronic device (CIED) or implanted neurostimulator while releasing antimicrobial agents over a minimum of seven days.

Takeda Pharmaceutical Company Limited announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.

Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as B.1.351 first identified in the Republic of South Africa, and has shipped doses to the National Institutes of Health (NIH) for a Phase 1 clinical trial that will be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

Union Health Minister Dr. Harsh Vardhan on Monday announced inclusion of “non-alcoholic fatty liver disease” into the National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), a move that will help manage the country’s burden of non-communicable diseases.

Understanding how the immune system responds to acute brain hemorrhage could open doors to identifying treatments for this devastating disease. However, up until now, there has been limited information on inflammation in the brain from human patients, especially during the first days after a hemorrhagic stroke.

This led a team of researchers to partner with a large clinical trial of minimally-invasive surgery to tackle defining the human neuroinflammatory response in living patients.

A federally approved heart medication shows significant effectiveness in interfering with SARS-CoV-2 entry into the human cell host, according to a new study by a research team from Texas A&M University and The University of Texas Medical Branch (UTMB).

The medication bepridil, which goes by the trade name Vascor, is currently approved by the U.S. Food and Drug Administration (FDA) to treat angina, a heart condition.